Dr Alan Taylor, PhD
Executive Chairperson
Alan joined the Board in November 2013 as Executive Chairperson.
Alan has been instrumental in the growth of the Company and has been heavily involved in all areas of the Company’s business. He has approximately 15 years of investment banking experience focused predominantly on the life sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, Alan was an Executive Director of Inteq Limited, a boutique Australian investment bank.
After receiving the University Medal for his undergraduate degree in Applied Science at the University of Sydney, Alan completed his PhD in Medicine at the Garvan Institute of Medical Research. Dr Taylor has also completed a Graduate Diploma in Applied Finance at the Securities Institute of Australia.
Michelle Parker
Chief Executive Officer, Managing Director
Michelle joined the Company in June 2018 and is the Company’s Chief Executive Officer and Managing Director. She joined Clarity’s Board in 2024.
Michelle has over 20 years of experience spanning across nuclear medicine/PET and pharmaceutical industries both in Australia and internationally. Prior to joining the Company, Michelle held the position of Head of International Clinical Research Operations at Novartis Australia, a global pharmaceutical company, leading a multi-disciplinary, high performing team of over 35 associates responsible for end-to-end clinical trial execution.
Michelle holds a Bachelor of Applied Science in Medical Radiation Technology (Nuclear Medicine) from the University of Sydney.
Eva Lengyelova
Executive Vice President – Clinical Development
Eva joined Clarity in 2017 and currently serves as Vice President of Clinical Development.
She is responsible for driving the Company’s global clinical development programs and, alongside the rest of the clinical team, advancing clinical development strategies with the goal of improving treatment outcomes for children and adults with cancer.
Eva is an experienced researcher with a deep understanding of oncology drug development, regulatory requirements, and clinical trial design. She is an avid learner, fluent in five languages, and holds a Bachelor’s degree in Biology and a Master’s in Molecular Biology from Comenius University in Bratislava, as well as a Master’s in Clinical Trials Research from the University of Sydney.
Lisa Sadetskaya
Director, Corporate Communications
Lisa joined the Company in September 2012 and is Clarity’s Director, Corporate Communications.
She has spent her career in the start-up and entrepreneurial fields across three continents. Over the last ten years at Clarity Lisa has been heavily involved in the Company’s capital raisings, strategy development, corporate affairs, content creation, marketing and Clarity’s internal culture and HR.
Lisa has completed a double Masters in Commerce and International Business at the University of Sydney.
Mary Bennett
Head, People & Culture
Mary joined the Company in March 2024 and is Clarity’s Head, People & Culture.
Mary has over 13 years of experience within the Pharmaceutical industry. Prior to joining Clarity Mary has held senior HR leadership roles within Recordati Rare Diseases, Biointelect and Novartis Pharmaceuticals Australia & New Zealand where she held a number of different roles including Head, People & Organisation for the Novartis Oncology ANZ business which saw her responsible for leading all facets of HR, and as a member of the Country Leadership Team was also actively involved in developing the strategy, vision and goals for the business.
Mary holds a Bachelor of Applied Psychology and a Graduate Diploma in Applied Psychology from the University of Canberra.
Dr Othon Gervasio
Chief Medical Officer
Othon joined the Company in May 2023 and is Clarity’s Chief Medical Officer.
He is an experienced senior leader with over 20 years in Research and Development (academic and clinical research) and Medical Affairs. Prior to joining Clarity, Othon was Medical Director at Novartis Pharmaceuticals, Australia and New Zealand. He has worked for 13 years at Novartis Pharmaceuticals and was involved in a wide range of projects, including clinical trials in oncology, the launch of several oncology products in various platforms, medical affairs strategy for therapies from pre-clinical to late-stage clinical development, as well as pre- and post-marketing authorisation.
Dr Ellen van Dam, PhD
Chief Scientific Officer
Ellen joined the Company in December 2025 as Chief Scientific Officer and was also Head of R&D at Clarity for nearly 10 years, from 2014 to 2023.
Ellen has accrued 20 years of experience in the discovery and development of radiopharmaceuticals and novel small molecule drug candidates. Prior to joining Clarity in December 2025, Ellen was VP of clinical imaging and translational science at Perspective Therapeutics. Ellen’s experience encompasses all facets of drug development, from early bench science to managing preclinical and IND enabling studies through to clinical development and oversight of early phase clinical trials.Ellen holds a Ph.D. in Cell Biology from the University of Utrecht.
Dr Colin Biggin, PhD
Chief Operating Officer
Colin is currently Chief Operating Officer at Clarity and has joined the Board in October 2019 after playing an instrumental role in enhancing and designing the Company’s product development and clinical programmes since he first joined the Company in January 2017.
Colin has over 15 years of radiopharmaceutical development and commercialisation experience. Colin previously served with Algeta ASA during the development and commercialisation of its product Xofigo® (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Colin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
Colin holds a Bachelor of Science (Honours) and a PhD from the University of Glasgow.
Shaemus Gleason
Executive Vice President – Operations
Shaemus joined the Company in May 2021 and is the Company’s Executive Vice President of Operations.
Shaemus has over 13 years of experience spanning across all facets of targeted radionuclide therapies and diagnostic radiopharmaceuticals. Prior to joining the Company, Shaemus was a member of the oncology strategy business unit at Bayer/Algeta where he was responsible for the technical operations in their phase I targeted alpha therapy development globally. Prior to this, he held a leadership role on the US commercial organisation supporting a marketed product Xofigo® (radium-223 dichloride) for metastatic prostate cancer.
David Green
Chief Financial Officer
David joined the Company in January 2022 and is now serving as Clarity’s Chief Financial Officer responsible for the overall financial management of the Company including IT.
David comes to the role with over 25 years’ experience in performing senior finance roles for listed and unlisted companies, including Pacific Dunlop Limited, Sigma Pharmaceuticals, Alchemia Limited, Chiquita Brands South Pacific Limited (now Costa Group) and Ellume Limited. David commenced his career with Ernst & Young in Australia and Europe.
As a proven CFO, David has extensive experience in complex operating environments across multiple geographies, private treaty and public company transactions, treasury operations and debt and equity markets.
David is a Chartered Accountant and holds a Bachelor of Economics (Monash University) and Masters of Applied Finance (Securities Institute of Australia).
Chris Horvath
Chief Commerical Officer
Chris Horvath joined Clarity in January 2026 as Chief Commercial Officer.
Chris brings over two decades of biopharmaceutical experience spanning R&D, commercial leadership and corporate operations with deep expertise in oncology and radiopharmaceuticals. Prior to joining Clarity, Chris held senior commercial leadership roles at POINT Biopharma, AdvanCell and Novartis/Advanced Accelerator Applications, where he led the global launches of PSMA-targeted platforms, including Pluvicto® and Locametz®.
Earlier in his career, he held progressively senior commercial roles at Janssen, Dendreon, Merck and Bayer, following his start as a research scientist at DuPont and the Novartis Institutes for BioMedical Research. Chris holds a Bachelor of Science in Chemistry and Biology from Wilfrid Laurier University, a Master of Science in Analytical Science from the University of Guelph and an MBA in Pharmaceutical Management and Marketing from Rutgers Business School.
Robert Vickery
Company Secretary
Robert joined the Company in July 2019 as Clarity’s Chief Financial Officer and is now serving as Company Secretary.
Robert is a finance and governance executive with over 30 years of experience and has had extensive involvement in life sciences and early stage businesses. Prior to joining the Company, Robert led the finance function at the previously ASX-listed company, Viralytics Limited, and was a key member of the due diligence target team during the trade sale negotiations and due diligence process with the purchaser of the company (Merck & Co), liaising with legal and investment banking teams, as well as leading the finance, IT and HR integration efforts post acquisition.
Robert holds a Bachelor of Commerce from the University of New South Wales and is an Associate